This is the authors' abstract. We don't add key points for this paper.
The concept of monitoring neuroleptic drugs by means of chemical or pharmacological assays is considered from a historical and strategic point of view. The objectives of compliance control, reduction of long-term exposure, titration to a therapeutic range, and solution of medicolegal problems are separately considered. The relative merits of chemically specific (mainly chromatographic) and clinically specific (radioreceptor) assays are considered. An algorithm for interpretation of a neuroleptic concentration measurement is presented.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Stephen H. Curry (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: